Indehaveren af markedsføringstilladelsen blev anmodet om at godtgøre indikation og dosering som drøftet under den seneste gensidige anerkendelsesprocedure.
The Marketing Authorisation Holder (MAH) was requested to substantiate the indication and posology as discussed during the recent MRP.